Detail akcie Harmony Biosci Rg online

Business Summary: Harmony Biosciences Holdings, Inc. is a pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. WAKIX was developed for the treatment of excessive daytime sleepiness (EDS) in pediatric patients, six years and older, with narcolepsy. HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist. ZYN002 is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). It also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Harmony Biosciences Holdings Inc revenues increased 22% to $624.7M. Net income increased 42% to $136.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Pharmaceutical Preparations segment income increase of 26% to $169.9M, United States segment income increase of 26% to $169.9M.